Abstract:In people with metabolic syndrome, episodic exposure of pancreatic beta cells to elevated levels of both glucose and free fatty acids (FFAs)-or glucolipotoxicity-can induce a loss of glucose-stimulated insulin secretion (GSIS). This in turn can lead to a chronic state of glucolipotoxicity and a sustained loss of GSIS, ushering in type 2 diabetes. Loss of GSIS reflects a decline in beta cell glucokinase (GK) expression associated with decreased nuclear levels of the pancreatic and duodenal homeobox 1 (PDX1) factor that drives its transcription, along with that of Glut2 and insulin. Glucolipotoxicity-induced production of reactive oxygen species (ROS), stemming from both mitochondria and the NOX2 isoform of NADPH oxidase, drives an increase in c-Jun N-terminal kinase (JNK) activity that promotes nuclear export of PDX1, and impairs autocrine insulin signaling; the latter effect decreases PDX1 expression at the transcriptional level and up-regulates beta cell apoptosis. Conversely, the incretin hormone glucagon-like peptide-1 (GLP-1) promotes nuclear import of PDX1 via cAMP signaling. Nutraceuticals that quell an increase in beta cell ROS production, that amplify or mimic autocrine insulin signaling, or that boost GLP-1 production, should help to maintain GSIS and suppress beta cell apoptosis in the face of glucolipotoxicity, postponing or preventing onset of type 2 diabetes. Nutraceuticals with potential in this regard include the following: phycocyanobilin-an inhibitor of NOX2; agents promoting mitophagy and mitochondrial biogenesis, such as ferulic acid, lipoic acid, melatonin, berberine, and astaxanthin; myo-inositol and high-dose biotin, which promote phosphatidylinositol 3-kinase (PI3K)/Akt activation; and prebiotics/probiotics capable of boosting GLP-1 secretion. Complex supplements or functional foods providing a selection of these agents might be useful for diabetes prevention.

Developmental Programming and Glucolipotoxicity: Insights on Beta Cell Inflammation and Diabetes

Beta Cell Physiological Dynamics and Dysfunctional Transitions in Response to Islet Inflammation in Obesity and Diabetes

Therapeutic opportunities for pancreatic β-cell ER stress in diabetes mellitus

Metabolic Adaptions/Reprogramming in Islet Beta-Cells in Response to Physiological Stimulators—What Are the Consequences

Er Stress and Srebp-1 Activation Are Implicated in Beta-Cell Glucolipotoxicity

Transcriptional Control of Pancreatic Β-Cell Identity and Plasticity During the Pathogenesis of Type 2 Diabetes.

Heterogeneous Development of Β-Cell Populations in Diabetes-Resistant and Susceptible Mice

Persistent Inflammatory Lipotoxicity Impedes Pancreatic β-cell Function in Diet-Induced Obese Mice Despite Correction of Glucotoxicity

Maintaining Effective Beta Cell Function in the Face of Metabolic Syndrome-Associated Glucolipotoxicity-Nutraceutical Options

Molecular Mechanism of Islet Β-Cell Functional Alternations During Type 2 Diabetes.

Modulating an oxidative-inflammatory cascade: potential new treatment strategy for improving glucose metabolism, insulin resistance, and vascular function

To Be or Not to Be: The Divergent Action and Metabolism of Sphingosine-1 Phosphate in Pancreatic Beta-Cells in Response to Cytokines and Fatty Acids

Metabolic and functional specialisations of the pancreatic beta cell: gene disallowance, mitochondrial metabolism and intercellular connectivity

Living Dangerously: Protective and Harmful ER Stress Responses in Pancreatic β-Cells

Targeting β-Cell Plasticity: A Promising Approach for Diabetes Treatment

Glucocorticoids Reprogram β-Cell Signaling to Preserve Insulin Secretion

The Impairment of Glucose-Stimulated Insulin Secretion in Pancreatic Β-Cells Caused by Prolonged Glucotoxicity and Lipotoxicity is Associated with Elevated Adaptive Antioxidant Response.

Inside the β Cell: Molecular Stress Response Pathways in Diabetes Pathogenesis

Role of fatty acids in the pathogenesis of ß-cell failure and Type-2 diabetes

Chronic oxidative stress as a mechanism for glucose toxicity of the beta cell in Type 2 diabetes

Intracellular lipid metabolism impairs β cell compensation during diet-induced obesity.